Clinical Trial Update: Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts [Phase 3]

View source ↗

Summary

This Phase 3 trial compares standard-dose versus low-dose Advagraf (tacrolimus extended-release) with or without ACE inhibitors/ARBs to evaluate histology and f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Advagraf (tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED